Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
75
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Claris Biotherapeutics, Inc.